Incannex Healthcare Inc. (Nasdaq: IXHL) announced that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE